Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F21%3A00074660" target="_blank" >RIV/65269705:_____/21:00074660 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/21:00122810
Result on the web
<a href="https://link.springer.com/article/10.1007%2Fs00277-021-04594-w" target="_blank" >https://link.springer.com/article/10.1007%2Fs00277-021-04594-w</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00277-021-04594-w" target="_blank" >10.1007/s00277-021-04594-w</a>
Alternative languages
Result language
angličtina
Original language name
Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience
Original language description
Infections are the primary cause of morbidity and mortality in multiple myeloma (MM) patients (pts). The aim of our retrospective analysis was to evaluate incidence and course of COVID-19 infection in a cohort of 351 MM outpatients treated with novel drugs. COVID-19 disease was detected in 50/351 pts (14%); median age was 68 years. Gender, ISS stage, and last treatment lines were as follows: male 32, female 18; ISS-I 19, ISS-II 20, ISS-III 11; daratumumab-based 15, lenalidomide-based 12, bortezomib-based 17, other 6. Positive PCR test at COVID-19 diagnosis was present in all pts; anti-myeloma treatment was interrupted. Hospitalizations for COVID-19 pneumonia were necessary for 28/50 pts (56%), 18/50 pts (36%) in standard unit (SU) 10/50 pts (20%) in intensive care unit (ICU), and 9/50 pts (18%) died. The statistically significant parameters for COVID-19 hospitalization were as follows: responsive versus non-responsive disease (p = 0.027), ECOG performance status 0-2 versus >= 3 (p = 0.014), presence of comorbidities (0-1 versus >= 2, p = 0.043). The statistically significant factors for COVID-19 death were as follows: ECOG 0-2 versus >= 3 (p = 0.001), presence of comorbidities (0-1 versus >= 2, p = 0.007), serious course of COVID-19 disease with ICU hospitalization (SU versus ICU, p = 0.001). None of the other studied risk factors was associated with poor outcome (age, gender, ISS stage, immunoparesis, type of anti-myeloma treatment). Full recovery from COVID-19 infection was observed in 41/50 pts (82%) in median of 32 days. The course of COVID-19 disease in MM pts was mostly moderate or serious with 56% of hospitalizations and 18% of deaths.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Annals of Hematology
ISSN
0939-5555
e-ISSN
—
Volume of the periodical
100
Issue of the periodical within the volume
10
Country of publishing house
US - UNITED STATES
Number of pages
6
Pages from-to
2541-2546
UT code for WoS article
000678464700001
EID of the result in the Scopus database
2-s2.0-85111260822